Skip to content

In The News

Oncoholdings licenses first prospective drug treatment

Download PDF >

Oncoholdings Licenses Selective Inhibitors of HDAC from TGen

Oncoholdings Inc., a pharmaceutical company focused on the acquisition and development of innovative anti-cancer therapeutics, today announced the exclusive license of a family of small molecule selective inhibitors of Histone Deacetylases (HDAC).
Read More >

Virtual Drug Discovery:
The New Paradigm

In February, Pfizer announced the closing of its R&D center in Sandwich, United Kingdom. Once the diamond of their drug development, the facility covered 80 acres, employed 2,400, and was known as "the home of Viagra.".
Read More >

About

Oncoholdings, Inc., is a pharmaceutical company focused on acquiring and developing the most promising preclinical and early clinical anti-cancer agents. Oncoholdings was founded by the world’s leading oncology scientists and leverages the unique insights and experiences of its founders and world class scientific advisory board.